#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=In 2030 , in Western Europe and in the ten most populous nations of the world , the estimated number of individuals with Parkinson ’s disease ( PD ) will be over 8 million .
3-1	17-19	In	_	_	_	_
3-2	20-24	2030	time[3]	new[3]	_	_
3-3	25-26	,	time[3]	new[3]	_	_
3-4	27-29	in	time[3]	new[3]	_	_
3-5	30-37	Western	time[3]|place[4]	new[3]|new[4]	_	_
3-6	38-44	Europe	time[3]|place[4]	new[3]|new[4]	_	_
3-7	45-48	and	time[3]	new[3]	_	_
3-8	49-51	in	time[3]	new[3]	_	_
3-9	52-55	the	time[3]|place[5]	new[3]|new[5]	_	_
3-10	56-59	ten	time[3]|place[5]	new[3]|new[5]	_	_
3-11	60-64	most	time[3]|place[5]	new[3]|new[5]	_	_
3-12	65-73	populous	time[3]|place[5]	new[3]|new[5]	_	_
3-13	74-81	nations	time[3]|place[5]	new[3]|new[5]	_	_
3-14	82-84	of	time[3]|place[5]	new[3]|new[5]	_	_
3-15	85-88	the	time[3]|place[5]|place[6]	new[3]|new[5]|new[6]	_	_
3-16	89-94	world	time[3]|place[5]|place[6]	new[3]|new[5]|new[6]	_	_
3-17	95-96	,	_	_	_	_
3-18	97-100	the	abstract[7]	new[7]	_	_
3-19	101-110	estimated	abstract[7]	new[7]	_	_
3-20	111-117	number	abstract[7]	new[7]	_	_
3-21	118-120	of	abstract[7]	new[7]	_	_
3-22	121-132	individuals	abstract[7]|person[8]	new[7]|new[8]	_	_
3-23	133-137	with	abstract[7]|person[8]	new[7]|new[8]	_	_
3-24	138-147	Parkinson	abstract[7]|person[8]|person[9]|abstract[10]	new[7]|new[8]|new[9]|new[10]	appos|coref|appos|coref	3-28[0_10]|8-17[55_9]|3-28[0_10]|8-17[55_9]
3-25	148-150	’s	abstract[7]|person[8]|person[9]|abstract[10]	new[7]|new[8]|new[9]|new[10]	_	_
3-26	151-158	disease	abstract[7]|person[8]|abstract[10]	new[7]|new[8]|new[10]	_	_
3-27	159-160	(	_	_	_	_
3-28	161-163	PD	abstract	giv	coref	5-26[25_0]
3-29	164-165	)	_	_	_	_
3-30	166-170	will	_	_	_	_
3-31	171-173	be	_	_	_	_
3-32	174-178	over	quantity[12]	new[12]	_	_
3-33	179-180	8	quantity[12]	new[12]	_	_
3-34	181-188	million	quantity[12]	new[12]	_	_
3-35	189-190	.	_	_	_	_

#Text=One of the main challenges to be faced will be the development of technological and cost-effective solutions to improve the healthcare of these patients .
4-1	191-194	One	abstract[13]	new[13]	coref	4-11[15_13]
4-2	195-197	of	abstract[13]	new[13]	_	_
4-3	198-201	the	abstract[13]|abstract[14]	new[13]|new[14]	coref	15-6[119_14]
4-4	202-206	main	abstract[13]|abstract[14]	new[13]|new[14]	_	_
4-5	207-217	challenges	abstract[13]|abstract[14]	new[13]|new[14]	_	_
4-6	218-220	to	_	_	_	_
4-7	221-223	be	_	_	_	_
4-8	224-229	faced	_	_	_	_
4-9	230-234	will	_	_	_	_
4-10	235-237	be	_	_	_	_
4-11	238-241	the	abstract[15]	giv[15]	_	_
4-12	242-253	development	abstract[15]	giv[15]	_	_
4-13	254-256	of	abstract[15]	giv[15]	_	_
4-14	257-270	technological	abstract[15]|abstract[16]	giv[15]|new[16]	coref	17-15[149_16]
4-15	271-274	and	abstract[15]|abstract[16]	giv[15]|new[16]	_	_
4-16	275-289	cost-effective	abstract[15]|abstract[16]	giv[15]|new[16]	_	_
4-17	290-299	solutions	abstract[15]|abstract[16]	giv[15]|new[16]	_	_
4-18	300-302	to	_	_	_	_
4-19	303-310	improve	_	_	_	_
4-20	311-314	the	abstract[17]	new[17]	coref	14-46[0_17]
4-21	315-325	healthcare	abstract[17]	new[17]	_	_
4-22	326-328	of	abstract[17]	new[17]	_	_
4-23	329-334	these	abstract[17]|person[18]	new[17]|new[18]	coref	14-34[114_18]
4-24	335-343	patients	abstract[17]|person[18]	new[17]|new[18]	_	_
4-25	344-345	.	_	_	_	_

#Text=Remote medical communications , for example in the form of telemedicine and decentralized care pathways , will inevitably become part of the clinical management of such disease .
5-1	346-352	Remote	abstract[19]	new[19]	_	_
5-2	353-360	medical	abstract[19]	new[19]	_	_
5-3	361-375	communications	abstract[19]	new[19]	_	_
5-4	376-377	,	abstract[19]	new[19]	_	_
5-5	378-381	for	abstract[19]	new[19]	_	_
5-6	382-389	example	abstract[19]	new[19]	_	_
5-7	390-392	in	abstract[19]	new[19]	_	_
5-8	393-396	the	abstract[19]|abstract[20]	new[19]|new[20]	_	_
5-9	397-401	form	abstract[19]|abstract[20]	new[19]|new[20]	_	_
5-10	402-404	of	abstract[19]|abstract[20]	new[19]|new[20]	_	_
5-11	405-417	telemedicine	abstract[19]|abstract[20]|abstract	new[19]|new[20]|new	_	_
5-12	418-421	and	abstract[19]|abstract[20]	new[19]|new[20]	_	_
5-13	422-435	decentralized	abstract[19]|abstract[20]|abstract[23]	new[19]|new[20]|new[23]	_	_
5-14	436-440	care	abstract[19]|abstract[20]|abstract|abstract[23]	new[19]|new[20]|new|new[23]	_	_
5-15	441-449	pathways	abstract[19]|abstract[20]|abstract[23]	new[19]|new[20]|new[23]	_	_
5-16	450-451	,	_	_	_	_
5-17	452-456	will	_	_	_	_
5-18	457-467	inevitably	_	_	_	_
5-19	468-474	become	_	_	_	_
5-20	475-479	part	_	_	_	_
5-21	480-482	of	_	_	_	_
5-22	483-486	the	abstract[24]	new[24]	_	_
5-23	487-495	clinical	abstract[24]	new[24]	_	_
5-24	496-506	management	abstract[24]	new[24]	_	_
5-25	507-509	of	abstract[24]	new[24]	_	_
5-26	510-514	such	abstract[24]|abstract[25]	new[24]|giv[25]	coref	8-20[0_25]
5-27	515-522	disease	abstract[24]|abstract[25]	new[24]|giv[25]	_	_
5-28	523-524	.	_	_	_	_

#Text=Among the tougher hurdles to overcome , there is the accurate , low-cost and objective quantification of the typical motor symptoms , which is a key issue for obtaining a complete indication of the patient ’s state of impairment .
6-1	525-530	Among	_	_	_	_
6-2	531-534	the	abstract[26]	new[26]	coref	17-7[146_26]
6-3	535-542	tougher	abstract[26]	new[26]	_	_
6-4	543-550	hurdles	abstract[26]	new[26]	_	_
6-5	551-553	to	_	_	_	_
6-6	554-562	overcome	_	_	_	_
6-7	563-564	,	_	_	_	_
6-8	565-570	there	_	_	_	_
6-9	571-573	is	_	_	_	_
6-10	574-577	the	abstract[27]	new[27]	_	_
6-11	578-586	accurate	abstract[27]	new[27]	_	_
6-12	587-588	,	abstract[27]	new[27]	_	_
6-13	589-597	low-cost	abstract[27]	new[27]	_	_
6-14	598-601	and	abstract[27]	new[27]	_	_
6-15	602-611	objective	abstract[27]	new[27]	_	_
6-16	612-626	quantification	abstract[27]	new[27]	_	_
6-17	627-629	of	abstract[27]	new[27]	_	_
6-18	630-633	the	abstract[27]|abstract[29]	new[27]|new[29]	coref	8-36[61_29]
6-19	634-641	typical	abstract[27]|abstract[29]	new[27]|new[29]	_	_
6-20	642-647	motor	abstract[27]|object|abstract[29]	new[27]|new|new[29]	coref	7-6
6-21	648-656	symptoms	abstract[27]|abstract[29]	new[27]|new[29]	_	_
6-22	657-658	,	_	_	_	_
6-23	659-664	which	_	_	_	_
6-24	665-667	is	_	_	_	_
6-25	668-669	a	abstract[30]	new[30]	coref	25-17[259_30]
6-26	670-673	key	abstract[30]	new[30]	_	_
6-27	674-679	issue	abstract[30]	new[30]	_	_
6-28	680-683	for	_	_	_	_
6-29	684-693	obtaining	_	_	_	_
6-30	694-695	a	abstract[31]	new[31]	_	_
6-31	696-704	complete	abstract[31]	new[31]	_	_
6-32	705-715	indication	abstract[31]	new[31]	_	_
6-33	716-718	of	abstract[31]	new[31]	_	_
6-34	719-722	the	abstract[31]|abstract[33]	new[31]|new[33]	_	_
6-35	723-730	patient	abstract[31]|person[32]|abstract[33]	new[31]|new[32]|new[33]	coref	12-28[95_32]
6-36	731-733	’s	abstract[31]|person[32]|abstract[33]	new[31]|new[32]|new[33]	_	_
6-37	734-739	state	abstract[31]|abstract[33]	new[31]|new[33]	_	_
6-38	740-742	of	abstract[31]|abstract[33]	new[31]|new[33]	_	_
6-39	743-753	impairment	abstract[31]|abstract[33]|abstract	new[31]|new[33]|new	coref	10-29
6-40	754-755	.	_	_	_	_

#Text=Since 1967 , when the motor effects of Levodopa ( LD ) on bradykinesia have been shown for the first time in a video , the way has been traced towards the quantification of movement disorders and their therapeutic response .
7-1	756-761	Since	_	_	_	_
7-2	762-766	1967	time	new	_	_
7-3	767-768	,	_	_	_	_
7-4	769-773	when	_	_	_	_
7-5	774-777	the	abstract[37]	new[37]	_	_
7-6	778-783	motor	object|abstract[37]	giv|new[37]	coref	13-15
7-7	784-791	effects	abstract[37]	new[37]	_	_
7-8	792-794	of	abstract[37]	new[37]	_	_
7-9	795-803	Levodopa	abstract[37]|substance	new[37]|new	appos	7-11
7-10	804-805	(	abstract[37]	new[37]	_	_
7-11	806-808	LD	abstract[37]|substance	new[37]|giv	_	_
7-12	809-810	)	abstract[37]	new[37]	_	_
7-13	811-813	on	abstract[37]	new[37]	_	_
7-14	814-826	bradykinesia	abstract[37]|abstract	new[37]|new	coref	15-35
7-15	827-831	have	_	_	_	_
7-16	832-836	been	_	_	_	_
7-17	837-842	shown	_	_	_	_
7-18	843-846	for	_	_	_	_
7-19	847-850	the	abstract[41]	new[41]	coref	13-5[0_41]
7-20	851-856	first	abstract[41]	new[41]	_	_
7-21	857-861	time	abstract[41]	new[41]	_	_
7-22	862-864	in	abstract[41]	new[41]	_	_
7-23	865-866	a	abstract[41]|abstract[42]	new[41]|new[42]	coref	24-16[244_42]
7-24	867-872	video	abstract[41]|abstract[42]	new[41]|new[42]	_	_
7-25	873-874	,	_	_	_	_
7-26	875-878	the	abstract[43]	new[43]	_	_
7-27	879-882	way	abstract[43]	new[43]	_	_
7-28	883-886	has	_	_	_	_
7-29	887-891	been	_	_	_	_
7-30	892-898	traced	_	_	_	_
7-31	899-906	towards	_	_	_	_
7-32	907-910	the	abstract[44]	new[44]	_	_
7-33	911-925	quantification	abstract[44]	new[44]	_	_
7-34	926-928	of	abstract[44]	new[44]	_	_
7-35	929-937	movement	abstract[44]|abstract|abstract[46]|abstract[47]	new[44]|new|new[46]|new[47]	coref|coref|coref|coref|coref|coref	9-28|9-29[0_46]|9-28|9-29[0_46]|9-28|9-29[0_46]
7-36	938-947	disorders	abstract[44]|abstract[46]|abstract[47]	new[44]|new[46]|new[47]	_	_
7-37	948-951	and	abstract[44]|abstract[47]	new[44]|new[47]	_	_
7-38	952-957	their	abstract[44]|abstract[47]|abstract[48]	new[44]|new[47]|new[48]	_	_
7-39	958-969	therapeutic	abstract[44]|abstract[47]|abstract[48]	new[44]|new[47]|new[48]	_	_
7-40	970-978	response	abstract[44]|abstract[47]|abstract[48]	new[44]|new[47]|new[48]	_	_
7-41	979-980	.	_	_	_	_

#Text=This pathway passes through semi-quantitative rating scales , such as the Hoehn and Yahr stage and unified Parkinson ’s disease rating scale ( UPDRS ) , which is still the gold standard scale for assessing symptoms in PD .
8-1	981-985	This	abstract[49]	new[49]	_	_
8-2	986-993	pathway	abstract[49]	new[49]	_	_
8-3	994-1000	passes	_	_	_	_
8-4	1001-1008	through	_	_	_	_
8-5	1009-1026	semi-quantitative	abstract[51]	new[51]	coref	12-8[90_51]
8-6	1027-1033	rating	abstract|abstract[51]	new|new[51]	coref	8-21
8-7	1034-1040	scales	abstract[51]	new[51]	_	_
8-8	1041-1042	,	abstract[51]	new[51]	_	_
8-9	1043-1047	such	abstract[51]	new[51]	_	_
8-10	1048-1050	as	abstract[51]	new[51]	_	_
8-11	1051-1054	the	abstract[51]|abstract[54]	new[51]|new[54]	_	_
8-12	1055-1060	Hoehn	abstract[51]|abstract|abstract[54]	new[51]|new|new[54]	_	_
8-13	1061-1064	and	abstract[51]|abstract[54]	new[51]|new[54]	_	_
8-14	1065-1069	Yahr	abstract[51]|person|abstract[54]	new[51]|new|new[54]	_	_
8-15	1070-1075	stage	abstract[51]|abstract[54]	new[51]|new[54]	_	_
8-16	1076-1079	and	_	_	_	_
8-17	1080-1087	unified	person[55]|abstract[58]	giv[55]|new[58]	appos|appos	8-24[0_58]|8-24[0_58]
8-18	1088-1097	Parkinson	person[55]|abstract[58]	giv[55]|new[58]	_	_
8-19	1098-1100	’s	person[55]|abstract[58]	giv[55]|new[58]	_	_
8-20	1101-1108	disease	abstract|abstract[58]	giv|new[58]	coref	8-38
8-21	1109-1115	rating	abstract|abstract[58]	giv|new[58]	_	_
8-22	1116-1121	scale	abstract[58]	new[58]	_	_
8-23	1122-1123	(	_	_	_	_
8-24	1124-1129	UPDRS	abstract	giv	coref	8-29[60_0]
8-25	1130-1131	)	_	_	_	_
8-26	1132-1133	,	_	_	_	_
8-27	1134-1139	which	_	_	_	_
8-28	1140-1142	is	_	_	_	_
8-29	1143-1148	still	abstract[60]	giv[60]	coref	9-4[0_60]
8-30	1149-1152	the	abstract[60]	giv[60]	_	_
8-31	1153-1157	gold	abstract[60]	giv[60]	_	_
8-32	1158-1166	standard	abstract[60]	giv[60]	_	_
8-33	1167-1172	scale	abstract[60]	giv[60]	_	_
8-34	1173-1176	for	_	_	_	_
8-35	1177-1186	assessing	_	_	_	_
8-36	1187-1195	symptoms	abstract[61]	giv[61]	coref	11-16[83_61]
8-37	1196-1198	in	abstract[61]	giv[61]	_	_
8-38	1199-1201	PD	abstract[61]|abstract	giv[61]|giv	coref	14-11
8-39	1202-1203	.	_	_	_	_

#Text=Evaluation through the UPDRS score is a subjective process that comes after a global clinical judgment for the diagnosis in which the experience of the specialist in movement disorders is crucial .
9-1	1204-1214	Evaluation	abstract[63]	new[63]	coref	9-7[66_63]
9-2	1215-1222	through	abstract[63]	new[63]	_	_
9-3	1223-1226	the	abstract[63]|abstract[65]	new[63]|new[65]	_	_
9-4	1227-1232	UPDRS	abstract[63]|abstract|abstract[65]	new[63]|giv|new[65]	coref	19-52
9-5	1233-1238	score	abstract[63]|abstract[65]	new[63]|new[65]	_	_
9-6	1239-1241	is	_	_	_	_
9-7	1242-1243	a	abstract[66]	giv[66]	coref	10-1[73_66]
9-8	1244-1254	subjective	abstract[66]	giv[66]	_	_
9-9	1255-1262	process	abstract[66]	giv[66]	_	_
9-10	1263-1267	that	_	_	_	_
9-11	1268-1273	comes	_	_	_	_
9-12	1274-1279	after	_	_	_	_
9-13	1280-1281	a	abstract[67]	new[67]	coref	10-24[77_67]
9-14	1282-1288	global	abstract[67]	new[67]	_	_
9-15	1289-1297	clinical	abstract[67]	new[67]	_	_
9-16	1298-1306	judgment	abstract[67]	new[67]	_	_
9-17	1307-1310	for	abstract[67]	new[67]	_	_
9-18	1311-1314	the	abstract[67]|abstract[68]	new[67]|new[68]	coref	11-4[81_68]
9-19	1315-1324	diagnosis	abstract[67]|abstract[68]	new[67]|new[68]	_	_
9-20	1325-1327	in	_	_	_	_
9-21	1328-1333	which	_	_	_	_
9-22	1334-1337	the	abstract[69]	new[69]	_	_
9-23	1338-1348	experience	abstract[69]	new[69]	_	_
9-24	1349-1351	of	abstract[69]	new[69]	_	_
9-25	1352-1355	the	abstract[69]|person[70]	new[69]|new[70]	coref	12-18[92_70]
9-26	1356-1366	specialist	abstract[69]|person[70]	new[69]|new[70]	_	_
9-27	1367-1369	in	abstract[69]|person[70]	new[69]|new[70]	_	_
9-28	1370-1378	movement	abstract[69]|person[70]|abstract	new[69]|new[70]|giv	coref	18-13[157_0]
9-29	1379-1388	disorders	abstract	giv	_	_
9-30	1389-1391	is	_	_	_	_
9-31	1392-1399	crucial	_	_	_	_
9-32	1400-1401	.	_	_	_	_

#Text=This process is , in fact , characterized by an intrinsic inter-rater variability due to the different experience of the examiners , influencing the final judgment on the impairment severity .
10-1	1402-1406	This	abstract[73]	giv[73]	coref	26-9[265_73]
10-2	1407-1414	process	abstract[73]	giv[73]	_	_
10-3	1415-1417	is	_	_	_	_
10-4	1418-1419	,	_	_	_	_
10-5	1420-1422	in	_	_	_	_
10-6	1423-1427	fact	_	_	_	_
10-7	1428-1429	,	_	_	_	_
10-8	1430-1443	characterized	_	_	_	_
10-9	1444-1446	by	_	_	_	_
10-10	1447-1449	an	abstract[74]	new[74]	_	_
10-11	1450-1459	intrinsic	abstract[74]	new[74]	_	_
10-12	1460-1471	inter-rater	abstract[74]	new[74]	_	_
10-13	1472-1483	variability	abstract[74]	new[74]	_	_
10-14	1484-1487	due	_	_	_	_
10-15	1488-1490	to	_	_	_	_
10-16	1491-1494	the	abstract[75]	new[75]	_	_
10-17	1495-1504	different	abstract[75]	new[75]	_	_
10-18	1505-1515	experience	abstract[75]	new[75]	_	_
10-19	1516-1518	of	abstract[75]	new[75]	_	_
10-20	1519-1522	the	abstract[75]|person[76]	new[75]|new[76]	_	_
10-21	1523-1532	examiners	abstract[75]|person[76]	new[75]|new[76]	_	_
10-22	1533-1534	,	_	_	_	_
10-23	1535-1546	influencing	_	_	_	_
10-24	1547-1550	the	abstract[77]	giv[77]	_	_
10-25	1551-1556	final	abstract[77]	giv[77]	_	_
10-26	1557-1565	judgment	abstract[77]	giv[77]	_	_
10-27	1566-1568	on	abstract[77]	giv[77]	_	_
10-28	1569-1572	the	abstract[77]|abstract[79]	giv[77]|new[79]	_	_
10-29	1573-1583	impairment	abstract[77]|abstract|abstract[79]	giv[77]|giv|new[79]	coref	14-8[108_0]
10-30	1584-1592	severity	abstract[77]|abstract[79]	giv[77]|new[79]	_	_
10-31	1593-1594	.	_	_	_	_

#Text=A percentage of incorrect diagnosis of 25 % has also been reported , especially when symptoms such as essential tremor , vascular parkinsonism and atypical parkinsonian syndromes manifest .
11-1	1595-1596	A	abstract[80]	new[80]	_	_
11-2	1597-1607	percentage	abstract[80]	new[80]	_	_
11-3	1608-1610	of	abstract[80]	new[80]	_	_
11-4	1611-1620	incorrect	abstract[80]|abstract[81]	new[80]|giv[81]	_	_
11-5	1621-1630	diagnosis	abstract[80]|abstract[81]	new[80]|giv[81]	_	_
11-6	1631-1633	of	abstract[80]|abstract[81]	new[80]|giv[81]	_	_
11-7	1634-1636	25	abstract[80]|abstract[81]|quantity[82]	new[80]|giv[81]|new[82]	_	_
11-8	1637-1638	%	abstract[80]|abstract[81]|quantity[82]	new[80]|giv[81]|new[82]	_	_
11-9	1639-1642	has	_	_	_	_
11-10	1643-1647	also	_	_	_	_
11-11	1648-1652	been	_	_	_	_
11-12	1653-1661	reported	_	_	_	_
11-13	1662-1663	,	_	_	_	_
11-14	1664-1674	especially	_	_	_	_
11-15	1675-1679	when	_	_	_	_
11-16	1680-1688	symptoms	abstract[83]	giv[83]	coref	15-10[121_83]
11-17	1689-1693	such	abstract[83]	giv[83]	_	_
11-18	1694-1696	as	abstract[83]	giv[83]	_	_
11-19	1697-1706	essential	abstract[83]|abstract[84]	giv[83]|new[84]	_	_
11-20	1707-1713	tremor	abstract[83]|abstract[84]	giv[83]|new[84]	_	_
11-21	1714-1715	,	abstract[83]	giv[83]	_	_
11-22	1716-1724	vascular	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
11-23	1725-1737	parkinsonism	abstract[83]|abstract[85]	giv[83]|new[85]	_	_
11-24	1738-1741	and	abstract[83]	giv[83]	_	_
11-25	1742-1750	atypical	abstract[83]|abstract[87]	giv[83]|new[87]	_	_
11-26	1751-1763	parkinsonian	abstract[83]|place|abstract[87]	giv[83]|new|new[87]	_	_
11-27	1764-1773	syndromes	abstract[83]|abstract[87]	giv[83]|new[87]	_	_
11-28	1774-1782	manifest	_	_	_	_
11-29	1783-1784	.	_	_	_	_

#Text=Another difficulty to overcome , shared by all clinical assessment scales , is the mandatory presence of the specialist : this strongly influences the clinical management of the patient , as all the therapeutic decisions are restricted at the time of the single medical examination .
12-1	1785-1792	Another	abstract[88]	new[88]	coref	12-14[91_88]
12-2	1793-1803	difficulty	abstract[88]	new[88]	_	_
12-3	1804-1806	to	_	_	_	_
12-4	1807-1815	overcome	_	_	_	_
12-5	1816-1817	,	_	_	_	_
12-6	1818-1824	shared	_	_	_	_
12-7	1825-1827	by	_	_	_	_
12-8	1828-1831	all	abstract[90]	giv[90]	_	_
12-9	1832-1840	clinical	abstract[90]	giv[90]	_	_
12-10	1841-1851	assessment	abstract|abstract[90]	new|giv[90]	coref	19-25[189_0]
12-11	1852-1858	scales	abstract[90]	giv[90]	_	_
12-12	1859-1860	,	_	_	_	_
12-13	1861-1863	is	_	_	_	_
12-14	1864-1867	the	abstract[91]	giv[91]	ana	12-21[0_91]
12-15	1868-1877	mandatory	abstract[91]	giv[91]	_	_
12-16	1878-1886	presence	abstract[91]	giv[91]	_	_
12-17	1887-1889	of	abstract[91]	giv[91]	_	_
12-18	1890-1893	the	abstract[91]|person[92]	giv[91]|giv[92]	coref	24-35[251_92]
12-19	1894-1904	specialist	abstract[91]|person[92]	giv[91]|giv[92]	_	_
12-20	1905-1906	:	_	_	_	_
12-21	1907-1911	this	abstract	giv	coref	24-31[250_0]
12-22	1912-1920	strongly	_	_	_	_
12-23	1921-1931	influences	_	_	_	_
12-24	1932-1935	the	abstract[94]	new[94]	coref	25-10[257_94]
12-25	1936-1944	clinical	abstract[94]	new[94]	_	_
12-26	1945-1955	management	abstract[94]	new[94]	_	_
12-27	1956-1958	of	abstract[94]	new[94]	_	_
12-28	1959-1962	the	abstract[94]|person[95]	new[94]|giv[95]	coref	13-13[101_95]
12-29	1963-1970	patient	abstract[94]|person[95]	new[94]|giv[95]	_	_
12-30	1971-1972	,	_	_	_	_
12-31	1973-1975	as	_	_	_	_
12-32	1976-1979	all	abstract[96]	new[96]	_	_
12-33	1980-1983	the	abstract[96]	new[96]	_	_
12-34	1984-1995	therapeutic	abstract[96]	new[96]	_	_
12-35	1996-2005	decisions	abstract[96]	new[96]	_	_
12-36	2006-2009	are	_	_	_	_
12-37	2010-2020	restricted	_	_	_	_
12-38	2021-2023	at	_	_	_	_
12-39	2024-2027	the	_	_	_	_
12-40	2028-2032	time	_	_	_	_
12-41	2033-2035	of	_	_	_	_
12-42	2036-2039	the	abstract[97]	new[97]	coref	19-45[0_97]
12-43	2040-2046	single	abstract[97]	new[97]	_	_
12-44	2047-2054	medical	abstract[97]	new[97]	_	_
12-45	2055-2066	examination	abstract[97]	new[97]	_	_
12-46	2067-2068	.	_	_	_	_

#Text=However , during the time interval between two consecutive examinations , the patient ’s motor status may change significantly , out of the examiner ’s sight .
13-1	2069-2076	However	_	_	_	_
13-2	2077-2078	,	_	_	_	_
13-3	2079-2085	during	_	_	_	_
13-4	2086-2089	the	time[99]	new[99]	_	_
13-5	2090-2094	time	abstract|time[99]	giv|new[99]	_	_
13-6	2095-2103	interval	time[99]	new[99]	_	_
13-7	2104-2111	between	time[99]	new[99]	_	_
13-8	2112-2115	two	time[99]|event[100]	new[99]|new[100]	_	_
13-9	2116-2127	consecutive	time[99]|event[100]	new[99]|new[100]	_	_
13-10	2128-2140	examinations	time[99]|event[100]	new[99]|new[100]	_	_
13-11	2141-2142	,	_	_	_	_
13-12	2143-2146	the	abstract[103]	new[103]	coref	26-14[266_103]
13-13	2147-2154	patient	person[101]|abstract[103]	giv[101]|new[103]	coref	23-11[0_101]
13-14	2155-2157	’s	person[101]|abstract[103]	giv[101]|new[103]	_	_
13-15	2158-2163	motor	object|abstract[103]	giv|new[103]	coref	15-10
13-16	2164-2170	status	abstract[103]	new[103]	_	_
13-17	2171-2174	may	_	_	_	_
13-18	2175-2181	change	_	_	_	_
13-19	2182-2195	significantly	_	_	_	_
13-20	2196-2197	,	_	_	_	_
13-21	2198-2201	out	_	_	_	_
13-22	2202-2204	of	_	_	_	_
13-23	2205-2208	the	abstract[105]	new[105]	_	_
13-24	2209-2217	examiner	person[104]|abstract[105]	new[104]|new[105]	_	_
13-25	2218-2220	’s	person[104]|abstract[105]	new[104]|new[105]	_	_
13-26	2221-2226	sight	abstract[105]	new[105]	_	_
13-27	2227-2228	.	_	_	_	_

#Text=The chance of monitoring any change of the impairment in PD subjects over time , possibly daily and in a domestic environment , could have a strong impact on the clinical management of the patients and , consequently , on the long-term costs for the healthcare system .
14-1	2229-2232	The	abstract[106]	new[106]	_	_
14-2	2233-2239	chance	abstract[106]	new[106]	_	_
14-3	2240-2242	of	_	_	_	_
14-4	2243-2253	monitoring	_	_	_	_
14-5	2254-2257	any	abstract[107]	new[107]	_	_
14-6	2258-2264	change	abstract[107]	new[107]	_	_
14-7	2265-2267	of	abstract[107]	new[107]	_	_
14-8	2268-2271	the	abstract[107]|abstract[108]	new[107]|giv[108]	coref	22-28[0_108]
14-9	2272-2282	impairment	abstract[107]|abstract[108]	new[107]|giv[108]	_	_
14-10	2283-2285	in	abstract[107]|abstract[108]	new[107]|giv[108]	_	_
14-11	2286-2288	PD	abstract[107]|abstract[108]|abstract|abstract[110]	new[107]|giv[108]|giv|new[110]	coref|coref|coref|coref	15-23[126_110]|15-25|15-23[126_110]|15-25
14-12	2289-2297	subjects	abstract[107]|abstract[108]|abstract[110]	new[107]|giv[108]|new[110]	_	_
14-13	2298-2302	over	abstract[107]|abstract[108]|abstract[110]	new[107]|giv[108]|new[110]	_	_
14-14	2303-2307	time	abstract[107]|abstract[108]|abstract[110]	new[107]|giv[108]|new[110]	_	_
14-15	2308-2309	,	_	_	_	_
14-16	2310-2318	possibly	_	_	_	_
14-17	2319-2324	daily	_	_	_	_
14-18	2325-2328	and	_	_	_	_
14-19	2329-2331	in	_	_	_	_
14-20	2332-2333	a	place[111]	new[111]	_	_
14-21	2334-2342	domestic	place[111]	new[111]	_	_
14-22	2343-2354	environment	place[111]	new[111]	_	_
14-23	2355-2356	,	_	_	_	_
14-24	2357-2362	could	_	_	_	_
14-25	2363-2367	have	_	_	_	_
14-26	2368-2369	a	abstract[112]	new[112]	_	_
14-27	2370-2376	strong	abstract[112]	new[112]	_	_
14-28	2377-2383	impact	abstract[112]	new[112]	_	_
14-29	2384-2386	on	abstract[112]	new[112]	_	_
14-30	2387-2390	the	abstract[112]|abstract[113]	new[112]|new[113]	_	_
14-31	2391-2399	clinical	abstract[112]|abstract[113]	new[112]|new[113]	_	_
14-32	2400-2410	management	abstract[112]|abstract[113]	new[112]|new[113]	_	_
14-33	2411-2413	of	abstract[112]|abstract[113]	new[112]|new[113]	_	_
14-34	2414-2417	the	abstract[112]|abstract[113]|person[114]	new[112]|new[113]|giv[114]	_	_
14-35	2418-2426	patients	abstract[112]|abstract[113]|person[114]	new[112]|new[113]|giv[114]	_	_
14-36	2427-2430	and	_	_	_	_
14-37	2431-2432	,	_	_	_	_
14-38	2433-2445	consequently	abstract[115]	new[115]	_	_
14-39	2446-2447	,	abstract[115]	new[115]	_	_
14-40	2448-2450	on	abstract[115]	new[115]	_	_
14-41	2451-2454	the	abstract[115]	new[115]	_	_
14-42	2455-2464	long-term	abstract[115]	new[115]	_	_
14-43	2465-2470	costs	abstract[115]	new[115]	_	_
14-44	2471-2474	for	abstract[115]	new[115]	_	_
14-45	2475-2478	the	abstract[115]|abstract[117]	new[115]|new[117]	_	_
14-46	2479-2489	healthcare	abstract[115]|abstract|abstract[117]	new[115]|giv|new[117]	_	_
14-47	2490-2496	system	abstract[115]|abstract[117]	new[115]|new[117]	_	_
14-48	2497-2498	.	_	_	_	_

#Text=In an attempt to address these challenges and quantify motor symptoms , motion analysis studies have played a growing role in managing subjects with PD , exploring kinematic variables on gait ; tremor ; bradykinesia and rigidity .
15-1	2499-2501	In	_	_	_	_
15-2	2502-2504	an	abstract[118]	new[118]	_	_
15-3	2505-2512	attempt	abstract[118]	new[118]	_	_
15-4	2513-2515	to	_	_	_	_
15-5	2516-2523	address	_	_	_	_
15-6	2524-2529	these	abstract[119]	giv[119]	_	_
15-7	2530-2540	challenges	abstract[119]	giv[119]	_	_
15-8	2541-2544	and	_	_	_	_
15-9	2545-2553	quantify	_	_	_	_
15-10	2554-2559	motor	object|abstract[121]	giv|giv[121]	coref|coref	17-29|17-29
15-11	2560-2568	symptoms	abstract[121]	giv[121]	_	_
15-12	2569-2570	,	_	_	_	_
15-13	2571-2577	motion	abstract|abstract[124]	new|new[124]	coref|coref	16-9|16-9
15-14	2578-2586	analysis	abstract|abstract[124]	new|new[124]	coref	16-9[138_0]
15-15	2587-2594	studies	abstract[124]	new[124]	_	_
15-16	2595-2599	have	_	_	_	_
15-17	2600-2606	played	_	_	_	_
15-18	2607-2608	a	abstract[125]	new[125]	_	_
15-19	2609-2616	growing	abstract[125]	new[125]	_	_
15-20	2617-2621	role	abstract[125]	new[125]	_	_
15-21	2622-2624	in	_	_	_	_
15-22	2625-2633	managing	_	_	_	_
15-23	2634-2642	subjects	abstract[126]	giv[126]	coref	26-18[268_126]
15-24	2643-2647	with	abstract[126]	giv[126]	_	_
15-25	2648-2650	PD	abstract[126]|abstract	giv[126]|giv	coref	18-15
15-26	2651-2652	,	_	_	_	_
15-27	2653-2662	exploring	_	_	_	_
15-28	2663-2672	kinematic	abstract[128]	new[128]	_	_
15-29	2673-2682	variables	abstract[128]	new[128]	_	_
15-30	2683-2685	on	_	_	_	_
15-31	2686-2690	gait	abstract	new	appos	15-33
15-32	2691-2692	;	_	_	_	_
15-33	2693-2699	tremor	abstract	giv	_	_
15-34	2700-2701	;	_	_	_	_
15-35	2702-2714	bradykinesia	abstract|abstract[132]	giv|new[132]	ana|ana	16-13[0_132]|16-13[0_132]
15-36	2715-2718	and	abstract[132]	new[132]	_	_
15-37	2719-2727	rigidity	abstract[132]|abstract	new[132]|new	_	_
15-38	2728-2729	.	_	_	_	_

#Text=Motion capture systems are the reference standard for motion analysis , but they are expensive and non-portable , so their use is limited to laboratory environments and scientific research rather than to a routine clinical use .
16-1	2730-2736	Motion	person	new	_	_
16-2	2737-2744	capture	_	_	_	_
16-3	2745-2752	systems	abstract	new	ana	16-20
16-4	2753-2756	are	_	_	_	_
16-5	2757-2760	the	abstract[136]	new[136]	_	_
16-6	2761-2770	reference	abstract[136]	new[136]	_	_
16-7	2771-2779	standard	abstract[136]	new[136]	_	_
16-8	2780-2783	for	abstract[136]	new[136]	_	_
16-9	2784-2790	motion	abstract[136]|abstract|abstract[138]	new[136]|giv|giv[138]	coref|coref	18-10[156_138]|18-10[156_138]
16-10	2791-2799	analysis	abstract[136]|abstract[138]	new[136]|giv[138]	_	_
16-11	2800-2801	,	_	_	_	_
16-12	2802-2805	but	_	_	_	_
16-13	2806-2810	they	abstract	giv	_	_
16-14	2811-2814	are	_	_	_	_
16-15	2815-2824	expensive	_	_	_	_
16-16	2825-2828	and	_	_	_	_
16-17	2829-2841	non-portable	_	_	_	_
16-18	2842-2843	,	_	_	_	_
16-19	2844-2846	so	_	_	_	_
16-20	2847-2852	their	abstract|abstract[141]	giv|new[141]	coref|coref	18-35[168_0]|18-35[168_0]
16-21	2853-2856	use	abstract[141]	new[141]	_	_
16-22	2857-2859	is	_	_	_	_
16-23	2860-2867	limited	_	_	_	_
16-24	2868-2870	to	_	_	_	_
16-25	2871-2881	laboratory	place|place[143]	new|new[143]	_	_
16-26	2882-2894	environments	place[143]	new[143]	_	_
16-27	2895-2898	and	_	_	_	_
16-28	2899-2909	scientific	abstract[144]	new[144]	_	_
16-29	2910-2918	research	abstract[144]	new[144]	_	_
16-30	2919-2925	rather	_	_	_	_
16-31	2926-2930	than	_	_	_	_
16-32	2931-2933	to	_	_	_	_
16-33	2934-2935	a	abstract[145]	new[145]	coref	18-23[161_145]
16-34	2936-2943	routine	abstract[145]	new[145]	_	_
16-35	2944-2952	clinical	abstract[145]	new[145]	_	_
16-36	2953-2956	use	abstract[145]	new[145]	_	_
16-37	2957-2958	.	_	_	_	_

#Text=Therefore , in order to overcome these hurdles , it is urgent to find automatic and cost-effective solutions , capable of providing accurate and objective kinematic measures of motor performance and automatic scores that are well correlated to the standard clinical ones .
17-1	2959-2968	Therefore	_	_	_	_
17-2	2969-2970	,	_	_	_	_
17-3	2971-2973	in	_	_	_	_
17-4	2974-2979	order	_	_	_	_
17-5	2980-2982	to	_	_	_	_
17-6	2983-2991	overcome	_	_	_	_
17-7	2992-2997	these	abstract[146]	giv[146]	_	_
17-8	2998-3005	hurdles	abstract[146]	giv[146]	_	_
17-9	3006-3007	,	_	_	_	_
17-10	3008-3010	it	abstract	new	cata	17-10[0_148]
17-11	3011-3013	is	_	_	_	_
17-12	3014-3020	urgent	_	_	_	_
17-13	3021-3023	to	abstract[148]	new[148]	_	_
17-14	3024-3028	find	abstract[148]	new[148]	_	_
17-15	3029-3038	automatic	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
17-16	3039-3042	and	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
17-17	3043-3057	cost-effective	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
17-18	3058-3067	solutions	abstract[148]|abstract[149]	new[148]|giv[149]	_	_
17-19	3068-3069	,	_	_	_	_
17-20	3070-3077	capable	_	_	_	_
17-21	3078-3080	of	_	_	_	_
17-22	3081-3090	providing	_	_	_	_
17-23	3091-3099	accurate	_	_	_	_
17-24	3100-3103	and	_	_	_	_
17-25	3104-3113	objective	abstract	new	coref|none	19-22[188_0]|17-25[0_188]
17-26	3114-3123	kinematic	abstract[150]	new[150]	_	_
17-27	3124-3132	measures	abstract[150]	new[150]	_	_
17-28	3133-3135	of	abstract[150]	new[150]	_	_
17-29	3136-3141	motor	abstract[150]|object|event[152]	new[150]|giv|new[152]	coref|coref	19-44|19-44
17-30	3142-3153	performance	abstract[150]|event[152]	new[150]|new[152]	_	_
17-31	3154-3157	and	abstract[150]	new[150]	_	_
17-32	3158-3167	automatic	abstract[150]|abstract[153]	new[150]|new[153]	_	_
17-33	3168-3174	scores	abstract[150]|abstract[153]	new[150]|new[153]	_	_
17-34	3175-3179	that	_	_	_	_
17-35	3180-3183	are	_	_	_	_
17-36	3184-3188	well	_	_	_	_
17-37	3189-3199	correlated	_	_	_	_
17-38	3200-3202	to	_	_	_	_
17-39	3203-3206	the	object[154]	new[154]	coref	19-30[190_154]
17-40	3207-3215	standard	object[154]	new[154]	_	_
17-41	3216-3224	clinical	object[154]	new[154]	_	_
17-42	3225-3229	ones	object[154]	new[154]	_	_
17-43	3230-3231	.	_	_	_	_

#Text=Recently , various technological approaches have been proposed for the analysis of movement in PD , including wearable sensor networks based on the use of inertial measurement units ( IMUs ) , smartphones and active vision systems based on new low-cost RGB-Depth optical devices such as Microsoft Kinect® ( Microsoft Corporation , Redmond , WA , USA ) and Intel RealSense® SR300 ( Intel Corporation , Santa Clara , CA , USA)[26 ] .
18-1	3232-3240	Recently	_	_	_	_
18-2	3241-3242	,	_	_	_	_
18-3	3243-3250	various	abstract[155]	new[155]	_	_
18-4	3251-3264	technological	abstract[155]	new[155]	_	_
18-5	3265-3275	approaches	abstract[155]	new[155]	_	_
18-6	3276-3280	have	_	_	_	_
18-7	3281-3285	been	_	_	_	_
18-8	3286-3294	proposed	_	_	_	_
18-9	3295-3298	for	_	_	_	_
18-10	3299-3302	the	abstract[156]	giv[156]	_	_
18-11	3303-3311	analysis	abstract[156]	giv[156]	_	_
18-12	3312-3314	of	abstract[156]	giv[156]	_	_
18-13	3315-3323	movement	abstract[156]|abstract[157]	giv[156]|giv[157]	_	_
18-14	3324-3326	in	abstract[156]|abstract[157]	giv[156]|giv[157]	_	_
18-15	3327-3329	PD	abstract[156]|abstract[157]|abstract	giv[156]|giv[157]|giv	coref	26-18
18-16	3330-3331	,	abstract[156]	giv[156]	_	_
18-17	3332-3341	including	abstract[156]	giv[156]	_	_
18-18	3342-3350	wearable	abstract[156]|object[160]	giv[156]|new[160]	_	_
18-19	3351-3357	sensor	abstract[156]|object|object[160]	giv[156]|new|new[160]	coref	20-27
18-20	3358-3366	networks	abstract[156]|object[160]	giv[156]|new[160]	_	_
18-21	3367-3372	based	_	_	_	_
18-22	3373-3375	on	_	_	_	_
18-23	3376-3379	the	abstract[161]	giv[161]	coref	22-33[232_161]
18-24	3380-3383	use	abstract[161]	giv[161]	_	_
18-25	3384-3386	of	abstract[161]	giv[161]	_	_
18-26	3387-3395	inertial	abstract[161]|abstract|object[164]	giv[161]|new|new[164]	_	_
18-27	3396-3407	measurement	abstract[161]|event|object[164]	giv[161]|new|new[164]	_	_
18-28	3408-3413	units	abstract[161]|object[164]	giv[161]|new[164]	_	_
18-29	3414-3415	(	_	_	_	_
18-30	3416-3420	IMUs	abstract	new	_	_
18-31	3421-3422	)	_	_	_	_
18-32	3423-3424	,	_	_	_	_
18-33	3425-3436	smartphones	object	new	_	_
18-34	3437-3440	and	_	_	_	_
18-35	3441-3447	active	abstract[168]	giv[168]	_	_
18-36	3448-3454	vision	abstract|abstract[168]	new|giv[168]	coref	20-7
18-37	3455-3462	systems	abstract[168]	giv[168]	_	_
18-38	3463-3468	based	_	_	_	_
18-39	3469-3471	on	_	_	_	_
18-40	3472-3475	new	object[169]	new[169]	_	_
18-41	3476-3484	low-cost	object[169]	new[169]	_	_
18-42	3485-3494	RGB-Depth	object[169]	new[169]	_	_
18-43	3495-3502	optical	object[169]	new[169]	_	_
18-44	3503-3510	devices	object[169]	new[169]	_	_
18-45	3511-3515	such	object[169]	new[169]	_	_
18-46	3516-3518	as	object[169]	new[169]	_	_
18-47	3519-3528	Microsoft	object[169]|organization|object[171]	new[169]|new|new[171]	coref|coref	18-50|18-50
18-48	3529-3536	Kinect®	object[169]|object[171]	new[169]|new[171]	_	_
18-49	3537-3538	(	object[169]	new[169]	_	_
18-50	3539-3548	Microsoft	object[169]|organization	new[169]|giv	_	_
18-51	3549-3560	Corporation	object[169]	new[169]	_	_
18-52	3561-3562	,	object[169]	new[169]	_	_
18-53	3563-3570	Redmond	object[169]	new[169]	_	_
18-54	3571-3572	,	object[169]	new[169]	_	_
18-55	3573-3575	WA	object[169]	new[169]	_	_
18-56	3576-3577	,	object[169]	new[169]	_	_
18-57	3578-3581	USA	object[169]|place	new[169]|new	_	_
18-58	3582-3583	)	object[169]	new[169]	_	_
18-59	3584-3587	and	object[169]	new[169]	_	_
18-60	3588-3593	Intel	object[169]|organization|object[176]	new[169]|new|new[176]	coref|appos|coref|appos	18-64|18-64[179_176]|18-64|18-64[179_176]
18-61	3594-3604	RealSense®	object[169]|abstract|object[176]	new[169]|new|new[176]	_	_
18-62	3605-3610	SR300	object[169]|object[176]	new[169]|new[176]	_	_
18-63	3611-3612	(	_	_	_	_
18-64	3613-3618	Intel	organization|organization[178]|object[179]	giv|new[178]|giv[179]	_	_
18-65	3619-3630	Corporation	organization[178]|object[179]	new[178]|giv[179]	_	_
18-66	3631-3632	,	object[179]	giv[179]	_	_
18-67	3633-3638	Santa	object[179]|place[180]	giv[179]|new[180]	_	_
18-68	3639-3644	Clara	object[179]|place[180]	giv[179]|new[180]	_	_
18-69	3645-3646	,	object[179]	giv[179]	_	_
18-70	3647-3649	CA	object[179]|place	giv[179]|new	_	_
18-71	3650-3651	,	object[179]	giv[179]	_	_
18-72	3652-3659	USA)[26	object[179]|place	giv[179]|new	_	_
18-73	3660-3661	]	_	_	_	_
18-74	3662-3663	.	_	_	_	_

#Text=On the basis of these considerations , we propose the integration of two different sensor-based subsystems as a single solution for the objective , accurate and automated assessment of some standard tasks for the upper and lower limbs , as defined in the motor examination section ( Section 3 ) of UPDRS .
19-1	3664-3666	On	_	_	_	_
19-2	3667-3670	the	abstract[183]	new[183]	_	_
19-3	3671-3676	basis	abstract[183]	new[183]	_	_
19-4	3677-3679	of	abstract[183]	new[183]	_	_
19-5	3680-3685	these	abstract[183]|abstract[184]	new[183]|new[184]	_	_
19-6	3686-3700	considerations	abstract[183]|abstract[184]	new[183]|new[184]	_	_
19-7	3701-3702	,	_	_	_	_
19-8	3703-3705	we	person	acc	_	_
19-9	3706-3713	propose	_	_	_	_
19-10	3714-3717	the	abstract[186]	new[186]	_	_
19-11	3718-3729	integration	abstract[186]	new[186]	_	_
19-12	3730-3732	of	abstract[186]	new[186]	_	_
19-13	3733-3736	two	abstract[186]|abstract[187]	new[186]|new[187]	_	_
19-14	3737-3746	different	abstract[186]|abstract[187]	new[186]|new[187]	_	_
19-15	3747-3759	sensor-based	abstract[186]|abstract[187]	new[186]|new[187]	_	_
19-16	3760-3770	subsystems	abstract[186]|abstract[187]	new[186]|new[187]	_	_
19-17	3771-3773	as	abstract[186]|abstract[187]	new[186]|new[187]	_	_
19-18	3774-3775	a	abstract[186]|abstract[187]	new[186]|new[187]	_	_
19-19	3776-3782	single	abstract[186]|abstract[187]	new[186]|new[187]	_	_
19-20	3783-3791	solution	abstract[186]|abstract[187]	new[186]|new[187]	_	_
19-21	3792-3795	for	abstract[186]|abstract[187]	new[186]|new[187]	_	_
19-22	3796-3799	the	abstract[186]|abstract[187]|abstract[188]	new[186]|new[187]|new[188]	_	_
19-23	3800-3809	objective	abstract[186]|abstract[187]|abstract[188]	new[186]|new[187]|new[188]	_	_
19-24	3810-3811	,	_	_	_	_
19-25	3812-3820	accurate	abstract[189]	giv[189]	_	_
19-26	3821-3824	and	abstract[189]	giv[189]	_	_
19-27	3825-3834	automated	abstract[189]	giv[189]	_	_
19-28	3835-3845	assessment	abstract[189]	giv[189]	_	_
19-29	3846-3848	of	abstract[189]	giv[189]	_	_
19-30	3849-3853	some	abstract[189]|abstract[190]	giv[189]|giv[190]	coref	20-14[202_190]
19-31	3854-3862	standard	abstract[189]|abstract[190]	giv[189]|giv[190]	_	_
19-32	3863-3868	tasks	abstract[189]|abstract[190]	giv[189]|giv[190]	_	_
19-33	3869-3872	for	abstract[189]|abstract[190]	giv[189]|giv[190]	_	_
19-34	3873-3876	the	abstract[189]|abstract[190]|object[191]	giv[189]|giv[190]|new[191]	coref	20-19[203_191]
19-35	3877-3882	upper	abstract[189]|abstract[190]|object[191]	giv[189]|giv[190]|new[191]	_	_
19-36	3883-3886	and	abstract[189]|abstract[190]|object[191]	giv[189]|giv[190]|new[191]	_	_
19-37	3887-3892	lower	abstract[189]|abstract[190]|object[191]	giv[189]|giv[190]|new[191]	_	_
19-38	3893-3898	limbs	abstract[189]|abstract[190]|object[191]	giv[189]|giv[190]|new[191]	_	_
19-39	3899-3900	,	_	_	_	_
19-40	3901-3903	as	_	_	_	_
19-41	3904-3911	defined	_	_	_	_
19-42	3912-3914	in	_	_	_	_
19-43	3915-3918	the	abstract[194]	new[194]	appos	19-48[195_194]
19-44	3919-3924	motor	object|abstract[194]	giv|new[194]	coref	20-15
19-45	3925-3936	examination	abstract|abstract[194]	giv|new[194]	_	_
19-46	3937-3944	section	abstract[194]	new[194]	_	_
19-47	3945-3946	(	_	_	_	_
19-48	3947-3954	Section	abstract[195]	giv[195]	coref	21-30[222_195]
19-49	3955-3956	3	abstract[195]	giv[195]	_	_
19-50	3957-3958	)	_	_	_	_
19-51	3959-3961	of	_	_	_	_
19-52	3962-3967	UPDRS	organization	giv	coref	21-13
19-53	3968-3969	.	_	_	_	_

#Text=The first component is an active vision system dedicated to the analysis of the motor tasks related to upper limbs ; the second applies a body sensor network ( BSN ) approach with wireless wearable sensors for the analysis of the lower limb tasks .
20-1	3970-3973	The	abstract[197]	new[197]	coref	20-5[199_197]
20-2	3974-3979	first	abstract[197]	new[197]	_	_
20-3	3980-3989	component	abstract[197]	new[197]	_	_
20-4	3990-3992	is	_	_	_	_
20-5	3993-3995	an	abstract[199]	giv[199]	coref	22-23[228_199]
20-6	3996-4002	active	abstract[199]	giv[199]	_	_
20-7	4003-4009	vision	abstract|abstract[199]	giv|giv[199]	_	_
20-8	4010-4016	system	abstract[199]	giv[199]	_	_
20-9	4017-4026	dedicated	_	_	_	_
20-10	4027-4029	to	_	_	_	_
20-11	4030-4033	the	abstract[200]	new[200]	_	_
20-12	4034-4042	analysis	abstract[200]	new[200]	_	_
20-13	4043-4045	of	abstract[200]	new[200]	_	_
20-14	4046-4049	the	abstract[200]|abstract[202]	new[200]|giv[202]	coref	20-41[213_202]
20-15	4050-4055	motor	abstract[200]|object|abstract[202]	new[200]|giv|giv[202]	coref	24-20
20-16	4056-4061	tasks	abstract[200]|abstract[202]	new[200]|giv[202]	_	_
20-17	4062-4069	related	_	_	_	_
20-18	4070-4072	to	_	_	_	_
20-19	4073-4078	upper	object[203]	giv[203]	_	_
20-20	4079-4084	limbs	object[203]	giv[203]	_	_
20-21	4085-4086	;	_	_	_	_
20-22	4087-4090	the	_	_	_	_
20-23	4091-4097	second	_	_	_	_
20-24	4098-4105	applies	_	_	_	_
20-25	4106-4107	a	object[206]	new[206]	_	_
20-26	4108-4112	body	organization|object[206]	new|new[206]	_	_
20-27	4113-4119	sensor	person|object[206]	giv|new[206]	_	_
20-28	4120-4127	network	object[206]	new[206]	_	_
20-29	4128-4129	(	_	_	_	_
20-30	4130-4133	BSN	organization	new	_	_
20-31	4134-4135	)	_	_	_	_
20-32	4136-4144	approach	abstract[208]	new[208]	coref	25-6[256_208]
20-33	4145-4149	with	abstract[208]	new[208]	_	_
20-34	4150-4158	wireless	abstract[208]|object|object[210]	new[208]|new|new[210]	_	_
20-35	4159-4167	wearable	abstract[208]|object[210]	new[208]|new[210]	_	_
20-36	4168-4175	sensors	abstract[208]|object[210]	new[208]|new[210]	_	_
20-37	4176-4179	for	abstract[208]|object[210]	new[208]|new[210]	_	_
20-38	4180-4183	the	abstract[208]|object[210]|abstract[211]	new[208]|new[210]|new[211]	_	_
20-39	4184-4192	analysis	abstract[208]|object[210]|abstract[211]	new[208]|new[210]|new[211]	_	_
20-40	4193-4195	of	abstract[208]|object[210]|abstract[211]	new[208]|new[210]|new[211]	_	_
20-41	4196-4199	the	abstract[208]|object[210]|abstract[211]|abstract[213]	new[208]|new[210]|new[211]|giv[213]	coref	23-17[239_213]
20-42	4200-4205	lower	abstract[208]|object[210]|abstract[211]|abstract[213]	new[208]|new[210]|new[211]|giv[213]	_	_
20-43	4206-4210	limb	abstract[208]|object[210]|abstract[211]|object|abstract[213]	new[208]|new[210]|new[211]|new|giv[213]	_	_
20-44	4211-4216	tasks	abstract[208]|object[210]|abstract[211]|abstract[213]	new[208]|new[210]|new[211]|giv[213]	_	_
20-45	4217-4218	.	_	_	_	_

#Text=The technical details of both and the validation of their accuracy as UPDRS automatic scoring systems have been already presented in previous works and will be briefly summarized in the Materials and Methods section .
21-1	4219-4222	The	abstract[214]|abstract[215]	new[214]|new[215]	_	_
21-2	4223-4232	technical	abstract[214]|abstract[215]	new[214]|new[215]	_	_
21-3	4233-4240	details	abstract[214]|abstract[215]	new[214]|new[215]	_	_
21-4	4241-4243	of	abstract[215]	new[215]	_	_
21-5	4244-4248	both	abstract[215]|abstract[216]	new[215]|new[216]	_	_
21-6	4249-4252	and	abstract[215]|abstract[216]	new[215]|new[216]	_	_
21-7	4253-4256	the	abstract[215]|abstract[216]	new[215]|new[216]	_	_
21-8	4257-4267	validation	abstract[215]|abstract[216]	new[215]|new[216]	_	_
21-9	4268-4270	of	abstract[215]|abstract[216]	new[215]|new[216]	_	_
21-10	4271-4276	their	abstract[215]|abstract[216]|abstract[217]	new[215]|new[216]|new[217]	_	_
21-11	4277-4285	accuracy	abstract[215]|abstract[216]|abstract[217]	new[215]|new[216]|new[217]	_	_
21-12	4286-4288	as	abstract[215]|abstract[216]|abstract[217]	new[215]|new[216]|new[217]	_	_
21-13	4289-4294	UPDRS	abstract[215]|abstract[216]|abstract[217]|abstract	new[215]|new[216]|new[217]|giv	coref	23-17
21-14	4295-4304	automatic	abstract[215]|abstract[216]|abstract[217]	new[215]|new[216]|new[217]	_	_
21-15	4305-4312	scoring	abstract[215]|abstract[216]|abstract[217]	new[215]|new[216]|new[217]	_	_
21-16	4313-4320	systems	abstract[215]|abstract[216]|abstract[217]	new[215]|new[216]|new[217]	_	_
21-17	4321-4325	have	_	_	_	_
21-18	4326-4330	been	_	_	_	_
21-19	4331-4338	already	_	_	_	_
21-20	4339-4348	presented	_	_	_	_
21-21	4349-4351	in	_	_	_	_
21-22	4352-4360	previous	abstract[219]	new[219]	_	_
21-23	4361-4366	works	abstract[219]	new[219]	_	_
21-24	4367-4370	and	_	_	_	_
21-25	4371-4375	will	_	_	_	_
21-26	4376-4378	be	_	_	_	_
21-27	4379-4386	briefly	_	_	_	_
21-28	4387-4397	summarized	_	_	_	_
21-29	4398-4400	in	_	_	_	_
21-30	4401-4404	the	abstract[222]	giv[222]	_	_
21-31	4405-4414	Materials	substance|abstract[222]	new|giv[222]	_	_
21-32	4415-4418	and	abstract[222]	giv[222]	_	_
21-33	4419-4426	Methods	object|abstract[222]	new|giv[222]	_	_
21-34	4427-4434	section	abstract[222]	giv[222]	_	_
21-35	4435-4436	.	_	_	_	_

#Text=A gesture-based human machine interface has been developed as part of the solution , to simplify the interaction and the self-management of the system by people with impairment , in view of a possible use at home .
22-1	4437-4438	A	abstract[224]	new[224]	_	_
22-2	4439-4452	gesture-based	abstract[224]	new[224]	_	_
22-3	4453-4458	human	abstract[224]	new[224]	_	_
22-4	4459-4466	machine	object|abstract[224]	new|new[224]	_	_
22-5	4467-4476	interface	abstract[224]	new[224]	_	_
22-6	4477-4480	has	_	_	_	_
22-7	4481-4485	been	_	_	_	_
22-8	4486-4495	developed	_	_	_	_
22-9	4496-4498	as	_	_	_	_
22-10	4499-4503	part	_	_	_	_
22-11	4504-4506	of	_	_	_	_
22-12	4507-4510	the	abstract[225]	new[225]	_	_
22-13	4511-4519	solution	abstract[225]	new[225]	_	_
22-14	4520-4521	,	_	_	_	_
22-15	4522-4524	to	_	_	_	_
22-16	4525-4533	simplify	_	_	_	_
22-17	4534-4537	the	event[226]	new[226]	_	_
22-18	4538-4549	interaction	event[226]	new[226]	_	_
22-19	4550-4553	and	_	_	_	_
22-20	4554-4557	the	abstract[227]	new[227]	_	_
22-21	4558-4573	self-management	abstract[227]	new[227]	_	_
22-22	4574-4576	of	abstract[227]	new[227]	_	_
22-23	4577-4580	the	abstract[227]|abstract[228]	new[227]|giv[228]	coref	23-1[234_228]
22-24	4581-4587	system	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
22-25	4588-4590	by	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
22-26	4591-4597	people	abstract[227]|abstract[228]|person[229]	new[227]|giv[228]|new[229]	_	_
22-27	4598-4602	with	abstract[227]|abstract[228]|person[229]	new[227]|giv[228]|new[229]	_	_
22-28	4603-4613	impairment	abstract[227]|abstract[228]|person[229]|abstract	new[227]|giv[228]|new[229]|giv	_	_
22-29	4614-4615	,	_	_	_	_
22-30	4616-4618	in	_	_	_	_
22-31	4619-4623	view	abstract[231]	new[231]	_	_
22-32	4624-4626	of	abstract[231]	new[231]	_	_
22-33	4627-4628	a	abstract[231]|abstract[232]	new[231]|giv[232]	_	_
22-34	4629-4637	possible	abstract[231]|abstract[232]	new[231]|giv[232]	_	_
22-35	4638-4641	use	abstract[231]|abstract[232]	new[231]|giv[232]	_	_
22-36	4642-4644	at	abstract[231]|abstract[232]	new[231]|giv[232]	_	_
22-37	4645-4649	home	abstract[231]|abstract[232]|place	new[231]|giv[232]|new	_	_
22-38	4650-4651	.	_	_	_	_

#Text=The system is able to analyze and automatically score the patient movements during the performance of UPDRS tasks .
23-1	4652-4655	The	abstract[234]	giv[234]	coref	25-24[262_234]
23-2	4656-4662	system	abstract[234]	giv[234]	_	_
23-3	4663-4665	is	_	_	_	_
23-4	4666-4670	able	_	_	_	_
23-5	4671-4673	to	_	_	_	_
23-6	4674-4681	analyze	_	_	_	_
23-7	4682-4685	and	_	_	_	_
23-8	4686-4699	automatically	_	_	_	_
23-9	4700-4705	score	_	_	_	_
23-10	4706-4709	the	abstract[236]	new[236]	_	_
23-11	4710-4717	patient	person|abstract[236]	giv|new[236]	coref	25-14[258_0]
23-12	4718-4727	movements	abstract[236]	new[236]	_	_
23-13	4728-4734	during	_	_	_	_
23-14	4735-4738	the	event[237]	new[237]	ana	24-4[0_237]
23-15	4739-4750	performance	event[237]	new[237]	_	_
23-16	4751-4753	of	event[237]	new[237]	_	_
23-17	4754-4759	UPDRS	event[237]|organization|abstract[239]	new[237]|giv|giv[239]	_	_
23-18	4760-4765	tasks	event[237]|abstract[239]	new[237]|giv[239]	_	_
23-19	4766-4767	.	_	_	_	_

#Text=In addition , it archives in the Cloud the kinematic data , the score and the video of each motor performance , guaranteeing the remote supervision by clinicians and overcoming the mandatory presence of the specialist during the execution of the motor activities .
24-1	4768-4770	In	_	_	_	_
24-2	4771-4779	addition	_	_	_	_
24-3	4780-4781	,	_	_	_	_
24-4	4782-4784	it	event	giv	coref	24-19[246_0]
24-5	4785-4793	archives	_	_	_	_
24-6	4794-4796	in	_	_	_	_
24-7	4797-4800	the	person[241]	new[241]	_	_
24-8	4801-4806	Cloud	person[241]	new[241]	_	_
24-9	4807-4810	the	abstract[242]	new[242]	appos	24-13[243_242]
24-10	4811-4820	kinematic	abstract[242]	new[242]	_	_
24-11	4821-4825	data	abstract[242]	new[242]	_	_
24-12	4826-4827	,	_	_	_	_
24-13	4828-4831	the	abstract[243]	giv[243]	_	_
24-14	4832-4837	score	abstract[243]	giv[243]	_	_
24-15	4838-4841	and	_	_	_	_
24-16	4842-4845	the	abstract[244]	giv[244]	_	_
24-17	4846-4851	video	abstract[244]	giv[244]	_	_
24-18	4852-4854	of	abstract[244]	giv[244]	_	_
24-19	4855-4859	each	abstract[244]|event[246]	giv[244]|giv[246]	_	_
24-20	4860-4865	motor	abstract[244]|object|event[246]	giv[244]|giv|giv[246]	coref	24-42
24-21	4866-4877	performance	abstract[244]|event[246]	giv[244]|giv[246]	_	_
24-22	4878-4879	,	_	_	_	_
24-23	4880-4892	guaranteeing	_	_	_	_
24-24	4893-4896	the	abstract[248]	new[248]	_	_
24-25	4897-4903	remote	object|abstract[248]	new|new[248]	_	_
24-26	4904-4915	supervision	abstract[248]	new[248]	_	_
24-27	4916-4918	by	abstract[248]	new[248]	_	_
24-28	4919-4929	clinicians	abstract[248]|person	new[248]|new	_	_
24-29	4930-4933	and	_	_	_	_
24-30	4934-4944	overcoming	_	_	_	_
24-31	4945-4948	the	abstract[250]	giv[250]	_	_
24-32	4949-4958	mandatory	abstract[250]	giv[250]	_	_
24-33	4959-4967	presence	abstract[250]	giv[250]	_	_
24-34	4968-4970	of	abstract[250]	giv[250]	_	_
24-35	4971-4974	the	abstract[250]|person[251]	giv[250]|giv[251]	_	_
24-36	4975-4985	specialist	abstract[250]|person[251]	giv[250]|giv[251]	_	_
24-37	4986-4992	during	_	_	_	_
24-38	4993-4996	the	event[252]	new[252]	_	_
24-39	4997-5006	execution	event[252]	new[252]	_	_
24-40	5007-5009	of	event[252]	new[252]	_	_
24-41	5010-5013	the	event[252]|abstract[254]	new[252]|new[254]	_	_
24-42	5014-5019	motor	event[252]|object|abstract[254]	new[252]|giv|new[254]	_	_
24-43	5020-5030	activities	event[252]|abstract[254]	new[252]|new[254]	_	_
24-44	5031-5032	.	_	_	_	_

#Text=Finally , in view of a decentralized approach to the clinical management of the patient , the issue of acceptability and usability of the integrated system has been evaluated through a standard questionnaire .
25-1	5033-5040	Finally	_	_	_	_
25-2	5041-5042	,	_	_	_	_
25-3	5043-5045	in	_	_	_	_
25-4	5046-5050	view	abstract[255]	new[255]	_	_
25-5	5051-5053	of	abstract[255]	new[255]	_	_
25-6	5054-5055	a	abstract[255]|abstract[256]	new[255]|giv[256]	coref	26-21[269_256]
25-7	5056-5069	decentralized	abstract[255]|abstract[256]	new[255]|giv[256]	_	_
25-8	5070-5078	approach	abstract[255]|abstract[256]	new[255]|giv[256]	_	_
25-9	5079-5081	to	abstract[255]|abstract[256]	new[255]|giv[256]	_	_
25-10	5082-5085	the	abstract[255]|abstract[256]|abstract[257]	new[255]|giv[256]|giv[257]	_	_
25-11	5086-5094	clinical	abstract[255]|abstract[256]|abstract[257]	new[255]|giv[256]|giv[257]	_	_
25-12	5095-5105	management	abstract[255]|abstract[256]|abstract[257]	new[255]|giv[256]|giv[257]	_	_
25-13	5106-5108	of	abstract[255]|abstract[256]|abstract[257]	new[255]|giv[256]|giv[257]	_	_
25-14	5109-5112	the	abstract[255]|abstract[256]|abstract[257]|person[258]	new[255]|giv[256]|giv[257]|giv[258]	_	_
25-15	5113-5120	patient	abstract[255]|abstract[256]|abstract[257]|person[258]	new[255]|giv[256]|giv[257]|giv[258]	_	_
25-16	5121-5122	,	_	_	_	_
25-17	5123-5126	the	abstract[259]	giv[259]	_	_
25-18	5127-5132	issue	abstract[259]	giv[259]	_	_
25-19	5133-5135	of	abstract[259]	giv[259]	_	_
25-20	5136-5149	acceptability	abstract[259]|abstract	giv[259]|new	_	_
25-21	5150-5153	and	abstract[259]	giv[259]	_	_
25-22	5154-5163	usability	abstract[259]|abstract[261]	giv[259]|new[261]	_	_
25-23	5164-5166	of	abstract[259]|abstract[261]	giv[259]|new[261]	_	_
25-24	5167-5170	the	abstract[259]|abstract[261]|abstract[262]	giv[259]|new[261]|giv[262]	coref	26-1[264_262]
25-25	5171-5181	integrated	abstract[259]|abstract[261]|abstract[262]	giv[259]|new[261]|giv[262]	_	_
25-26	5182-5188	system	abstract[259]|abstract[261]|abstract[262]	giv[259]|new[261]|giv[262]	_	_
25-27	5189-5192	has	_	_	_	_
25-28	5193-5197	been	_	_	_	_
25-29	5198-5207	evaluated	_	_	_	_
25-30	5208-5215	through	_	_	_	_
25-31	5216-5217	a	abstract[263]	new[263]	_	_
25-32	5218-5226	standard	abstract[263]	new[263]	_	_
25-33	5227-5240	questionnaire	abstract[263]	new[263]	_	_
25-34	5241-5242	.	_	_	_	_

#Text=The integrated system here presented is aimed at a more comprehensive evaluation of the neuro-motor status of PD subjects by a decentralized approach , and could represent a new example of an accurate , feasible and cost-effective strategy for the clinical management of PD .
26-1	5243-5246	The	abstract[264]	giv[264]	_	_
26-2	5247-5257	integrated	abstract[264]	giv[264]	_	_
26-3	5258-5264	system	abstract[264]	giv[264]	_	_
26-4	5265-5269	here	_	_	_	_
26-5	5270-5279	presented	_	_	_	_
26-6	5280-5282	is	_	_	_	_
26-7	5283-5288	aimed	_	_	_	_
26-8	5289-5291	at	_	_	_	_
26-9	5292-5293	a	abstract[265]	giv[265]	_	_
26-10	5294-5298	more	abstract[265]	giv[265]	_	_
26-11	5299-5312	comprehensive	abstract[265]	giv[265]	_	_
26-12	5313-5323	evaluation	abstract[265]	giv[265]	_	_
26-13	5324-5326	of	abstract[265]	giv[265]	_	_
26-14	5327-5330	the	abstract[265]|abstract[266]	giv[265]|giv[266]	_	_
26-15	5331-5342	neuro-motor	abstract[265]|abstract[266]	giv[265]|giv[266]	_	_
26-16	5343-5349	status	abstract[265]|abstract[266]	giv[265]|giv[266]	_	_
26-17	5350-5352	of	abstract[265]|abstract[266]	giv[265]|giv[266]	_	_
26-18	5353-5355	PD	abstract[265]|abstract[266]|abstract|abstract[268]	giv[265]|giv[266]|giv|giv[268]	coref|coref	26-44|26-44
26-19	5356-5364	subjects	abstract[265]|abstract[266]|abstract[268]	giv[265]|giv[266]|giv[268]	_	_
26-20	5365-5367	by	abstract[265]|abstract[266]	giv[265]|giv[266]	_	_
26-21	5368-5369	a	abstract[265]|abstract[266]|abstract[269]	giv[265]|giv[266]|giv[269]	_	_
26-22	5370-5383	decentralized	abstract[265]|abstract[266]|abstract[269]	giv[265]|giv[266]|giv[269]	_	_
26-23	5384-5392	approach	abstract[265]|abstract[266]|abstract[269]	giv[265]|giv[266]|giv[269]	_	_
26-24	5393-5394	,	_	_	_	_
26-25	5395-5398	and	_	_	_	_
26-26	5399-5404	could	_	_	_	_
26-27	5405-5414	represent	_	_	_	_
26-28	5415-5416	a	abstract[270]	new[270]	_	_
26-29	5417-5420	new	abstract[270]	new[270]	_	_
26-30	5421-5428	example	abstract[270]	new[270]	_	_
26-31	5429-5431	of	abstract[270]	new[270]	_	_
26-32	5432-5434	an	abstract[270]|abstract[271]	new[270]|new[271]	_	_
26-33	5435-5443	accurate	abstract[270]|abstract[271]	new[270]|new[271]	_	_
26-34	5444-5445	,	abstract[270]|abstract[271]	new[270]|new[271]	_	_
26-35	5446-5454	feasible	abstract[270]|abstract[271]	new[270]|new[271]	_	_
26-36	5455-5458	and	abstract[270]|abstract[271]	new[270]|new[271]	_	_
26-37	5459-5473	cost-effective	abstract[270]|abstract[271]	new[270]|new[271]	_	_
26-38	5474-5482	strategy	abstract[270]|abstract[271]	new[270]|new[271]	_	_
26-39	5483-5486	for	abstract[270]|abstract[271]	new[270]|new[271]	_	_
26-40	5487-5490	the	abstract[270]|abstract[271]|abstract[272]	new[270]|new[271]|new[272]	_	_
26-41	5491-5499	clinical	abstract[270]|abstract[271]|abstract[272]	new[270]|new[271]|new[272]	_	_
26-42	5500-5510	management	abstract[270]|abstract[271]|abstract[272]	new[270]|new[271]|new[272]	_	_
26-43	5511-5513	of	abstract[270]|abstract[271]|abstract[272]	new[270]|new[271]|new[272]	_	_
26-44	5514-5516	PD	abstract[270]|abstract[271]|abstract[272]|abstract	new[270]|new[271]|new[272]|giv	_	_
26-45	5517-5518	.	_	_	_	_
